AKT1 and melanoma: Corrales and colleagues described that the PI3K/Akt pathway is overactivated in melanoma cells made resistant to MAPK/ERK inhibitors (vemurafenib or trametinib) and is associated with increasing cell quiescence and migratory properties; notably, treatment of these cells with the dual PI3K/mTOR inhibitor dactolisib markedly reverts their stem-like properties [207].